Amgen Shares Surge on Strong Earnings and Cardiovascular Drug Breakthrough

Amgen US0311621009

Biotechnology leader Amgen is experiencing a significant rally, propelled by a powerful combination of exceptional financial performance and a major clinical achievement. The company’s latest quarterly report shattered forecasts, while groundbreaking trial data for its heart medication Repatha has generated substantial market optimism.

Amgen delivered a standout financial performance for the third quarter of 2025. The company reported earnings per share of $5.64, decisively beating analyst estimates by a notable 63 cents. Revenue growth was equally impressive, climbing 12.4% year-over-year to reach $9.56 billion. These results not only demonstrate the firm’s operational strength but also highlight its exceptional profitability, evidenced by a net margin approaching 19%.